Cornea

The primary endpoint will be pain improvement as measured by visual analogue scale (VAS) compared to placebo.

What to know about evolving guidelines and potential medicolegal risks.

As part of the sports and performance vision section of the AOA, Vittorio Mena, OD, MS, shares information on how to bolster athletes' performance through enhanced vision care.

Drs Clark Chang and Tracy Lynn Schroeder Swartz give an overview of their Optometry's Meeting talk on detecting keratoconus early, providing tips for the proper technology to use and how to properly detect high-risk patients.

Gromacki shares the importance of a dedicated approach to treating keratoconus, highlighting the need for passion, diverse tools, and a committed practice environment to ensure patient success.

The study also discovered a need for more blatant labeling on e-liquid containers to help reduce accidental contact with the ocular surface.

The company plans to finalize its Phase 3 development plans following an End-of-Phase 2 meeting with the FDA.

The study demonstrated sustained safety and efficacy of cyclosporine ophthalmic solution (Vevye) 0.1%, with many patients now entering their sixth refill cycle, according to the company.

The pachymeter is the most lightweight handheld product of its kind on the market, according to the company.

Investigators found more cases than expected following tomography of 2007 eyes.

Michael Belin, MD, weighs the ABCD and Amsler-Krumeich classifications and proposes ABCD progression displays as an effective modern alternative.

Phase 3 trials continue to investigate the efficacy of EpiSmart, a new method of cross-linking that could be utilized in the treatment of keratoconus.

Kourtney Houser, MD, and Kendall Donaldson, MD, MS, give an overview of the important role topography and tomography play in catching keratoconus early in their patients.

Early diagnosis of keratoconus is vital given the disease's prevalence in pediatric patient, according to Jennifer Harthan, OD, FAAO, FSLS.

Shelley Cutler, OD, FAAO, comments on technological advancements leading to the progression of keratoconus diagnosis and treatment options during this year's IKA symposium.

Melissa Barnett, OD, Director of Optometry at the University of California, Davis, talked about her session at IKA that focused on keratoconus from the patient perspective.

Justin Schweitzer, OD, FAAO, from Vance Thompson Vision, talked about his session at the IKA Symposium that discussed cross-linking in keratoconus treatment both now and looking toward the future.

Barry Eiden, OD, FAAO, FSLS, President and Co-founder of IKA, talked about his session at the meeting centering around the pediatric prevalence of keratoconus, the importance of early diagnosis, and the impact this can have on practices.

Alan Glazier, OD, FAAO, talked about moderating a session discussing the education of the public on keratoconus, from screening to diagnosis, and the roles clinicians can take to assist in the patients' anxieties.

Andrew Morgenstern, OD, FAAO, FNAP, President and Co-founder of IKA, talked about his session at the meeting that discussed the prevalence of keratoconus in the pediatric population in the US.

The 2 FDA registration trials for perfluorohexyloctane resulted in scientifically significant results for improvement of mild and moderate symptoms of dry eye disease.

The collective enhances education, research, and quality of life.

Controversies in Modern Eye Care cochair Arjan Hura, MD, details new expansions to the conference's schedule, which include discussions on retina gene therapies, corneal endothelial diseases, and oculoplastics.

The IOL launch is the company’s second market debut in less than 12 months.

What axial length readings and crystalline lens power tell you.

Pterygium is an ocular disease commonly referred to as “surfer’s eye,” which can result from exposure to high levels of UV radiation.

Before the ASCRS 2024 meeting, TheiaNova CEO Carissa Fonseca, PhD, pitched a novel keratoconus treatment.

The study authors also noted that patients responding well to routine intense pulsed light sessions do not need to undergo additional sessions.

The 1-time, intracameral injection is a cell therapy for the treatment of corneal edema secondary to corneal endothelial dysfunction.

Shifting the treatment paradigm can lead to less pain, inflammation